Review Article: Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program

ICU Director

Volumn 1, Issue 2, 2010, Pages 77-81

  Spencer Yost, C ^a   Daud, Adil ^b   Gropper, Michael A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Medical Center at Parnassus   (United States)

Author keywords

biotherapy; cancer; cytokine; immunostimulation; interleukin 2; melanoma; metastasis; renal cell carcinoma

Indexed keywords

GADOLINIUM; INTERLEUKIN 2;

ADVERSE OUTCOME; ANTIGEN RECOGNITION; CANCER CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CELL POLARITY; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HOSPITAL PATIENT; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; KIDNEY CARCINOMA; LUNG CANCER; LUNG DIFFUSION CAPACITY; MELANOMA; METASTASIS; MOLECULAR MODEL; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SCREENING TEST; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR REGRESSION;

EID: 84869740945     PISSN: 19444516     EISSN: 19444524     Source Type: Journal    
DOI: 10.1177/1944451610363596     Document Type: Review

References (13)

1. Rosenberg SA, Lotze MT, Muul LM,et al.Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485-1492.
2. Lewko WM, Oldham RK Cytokines. In: RK, Oldham ed. Principles of Cancer Biotherapy. 4th ed. Dordrecht, Germany: Kluwer Academic Publishers; 2003:183-299.
3. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193:1007-1008.
4. Gillis S., Ferm MM, Ou W., Smith KA T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978;120:2027-2032.
5. Skibber JM, Lotze MT, Muul LM, Uppenkamp IK, Ross W., Rosenberg SA Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell. Nat Immun Cell Growth Regul. 1987;6:291-305.
6. Antony PA, Restifo NP CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005;28:120-128.
7. Rosenberg SA, Lotze MT, Muul LM,et al.A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery. 1986;100:262-272.
8. Margolin KA, Rayner AA, Hawkins MJ,et al.Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7:486-498.
9. Lotze MT, Chang AE, Seipp CA, Simpson C., Vetto JT, Rosenberg SA High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA. 1986;256:3117-3124.
10. Passalacqua R., Buzio C., Buti S.,et al.Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol Immunother. 2001;59(4):553-561.
11. Gallagher DC, Bhatt RS, Parikh SM,et al.Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res. 2007;13:2115-2120.
12. Singla A., Denmeade SR Left posterior fascicular block due to high-dose interleukin-2. Ann Pharmacother. 2008;42:1340-1343.
13. Poncet MC, Toullic P., Papazian L.,et al.Burnout syndrome in critical care nursing staff. Am J Respir Crit Care Med. 2007;175:698-704.